Design Therapeutics
Yahoo Finance • 3 days ago
Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As Q1 2026 earnings season approaches, the healthcare sector enters reporting season as one of the market's primary... Full story
Yahoo Finance • 5 months ago
Design Therapeutics to Participate in Upcoming Investor Conferences
CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will pa... Full story
Yahoo Finance • 5 months ago
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelial Corneal Dystrophy (FECD) Ongoing Cas... Full story
Yahoo Finance • 7 months ago
Design Therapeutics Appoints Justin Gover to Board of Directors
CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of ind... Full story
Yahoo Finance • 8 months ago
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will pa... Full story
Yahoo Finance • 8 months ago
KORU Medical Systems And 2 Other Penny Stocks To Watch For Growth
As the U.S. stock market continues to reach new heights, with major indices like the S&P 500 and Nasdaq Composite hitting all-time highs, investors are increasingly optimistic about future growth prospects. In this context, penny stocks—th... Full story
Yahoo Finance • 12 months ago
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that it will present a... Full story
Yahoo Finance • 12 months ago
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the... Full story
Yahoo Finance • last year
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025 Dosing Complete in DT-168 Phase 1 Healthy Volunteer Trial, with Data on Track for the First Half o... Full story
Yahoo Finance • last year
Design Therapeutics to Participate in Leerink’s Global Healthcare Conference
CARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will p... Full story
Yahoo Finance • 2 years ago
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround Current Cash and Securities of ~$290M Support Extended Five-Year Operating Runway Through 2028 Revised Corporate Strategy with Realign... Full story
Yahoo Finance • 3 years ago
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
Initial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Showed Significant Increase in FXN mRNA Levels in Skeletal Muscle Company Expects to Resume a Multiple Dose Phase 1 Clinical Study with DT-216 with an... Full story
Yahoo Finance • 3 years ago
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
DT-216 Resulted in a Significant Increase in FXN mRNA Levels in Skeletal Muscle of FA Patients Treatment Generally Well-Tolerated; Injection Site Reactions Attributable to Current Formulation Composition Design Plans to Proceed with an I... Full story
Yahoo Finance • 3 years ago
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
Treatment with DT-168 Eye Drops Reduced Nuclear Foci and Significantly Improved Mis-Splicing In Vitro Company On-track to Submit Investigational New Drug Application for DT-168 in the Second Half of 2023 CARLSBAD, Calif., April 24, 20... Full story
Yahoo Finance • 3 years ago
Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Ongoing with Data Expected Mid-Year Continued Progress Across Pipeline of GeneTAC™ Small Molecules with Three Programs Expected to be in Clinical Development in the Nex... Full story
Yahoo Finance • 3 years ago
Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
CARLSBAD, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that João Siffert, M.D.... Full story
Yahoo Finance • 3 years ago
DESIGN ALERT: Bragar Eagel & Squire, P.C. is Investigating Design Therapeutics, Inc. on Behalf of Design Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Design Therapeutics, Inc. (“Design” or the “Company”) (NASDAQ: DSGN)... Full story
Yahoo Finance • 3 years ago
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
Initial Data from Single-Ascending Dose Phase 1 Trial of DT-216 for Friedreich Ataxia Expected to be Reported in December 2022 Dosing Initiated in the Multiple-Ascending Dose Phase 1 Trial of DT-216; Trial Completion Anticipated in Mid-20... Full story
Yahoo Finance • 4 years ago
Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results
Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 Expected in the Fourth Quarter of 2022 Strong Financial Position with $359.4 Million in Cash and Securities to Support Multi-Year Operating Runway CARLSBAD, Calif., Aug. 08, 20... Full story
Yahoo Finance • 4 years ago
Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results
Clinical Execution of Lead GeneTAC™ Molecule, DT-216, with Initiation of Phase 1 Trial for the Treatment of Friedreich Ataxia Robust Research Pipeline of GeneTAC™ Candidates, with Promising New Data for Fuchs Endothelial Corneal Dystrophy... Full story
